Spruce Biosciences, Inc. (NASDAQ:SPRB) Receives $169.67 Average Price Target from Analysts

Posted by on Jun 17th, 2026

Spruce Biosciences, Inc. (NASDAQ:SPRB – Get Free Report) has been given an average rating of “Moderate Buy” by the ten research firms that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $163.00.

A number of equities analysts have recently weighed in on SPRB shares. JonesTrading started coverage on Spruce Biosciences in a report on Tuesday, June 9th. They set a “buy” rating and a $135.00 price target for the company. Oppenheimer reiterated an “outperform” rating on shares of Spruce Biosciences in a report on Wednesday, May 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of Spruce Biosciences in a research note on Friday, June 5th. Citizens Jmp decreased their target price on Spruce Biosciences from $170.00 to $150.00 and set a “market outperform” rating on the stock in a research note on Thursday, May 14th. Finally, HC Wainwright decreased their target price on Spruce Biosciences from $200.00 to $150.00 and set a “buy” rating on the stock in a research note on Monday, June 1st.

Check Out Our Latest Stock Analysis on Spruce Biosciences

Hedge Funds Weigh In On Spruce Biosciences

Several hedge funds have recently bought and sold shares of the company. Stempoint Capital LP acquired a new position in Spruce Biosciences during the 1st quarter worth about $416,000. ADAR1 Capital Management LLC lifted its stake in Spruce Biosciences by 1.0% during the 1st quarter. ADAR1 Capital Management LLC now owns 58,600 shares of the company’s stock worth $3,830,000 after acquiring an additional 600 shares in the last quarter. SkyView Investment Advisors LLC acquired a new position in Spruce Biosciences during the 4th quarter worth about $261,000. Ikarian Capital LLC lifted its stake in Spruce Biosciences by 810.3% during the 4th quarter. Ikarian Capital LLC now owns 121,356 shares of the company’s stock worth $10,571,000 after acquiring an additional 108,024 shares in the last quarter. Finally, Wellington Management Group LLP acquired a new position in Spruce Biosciences during the 4th quarter worth about $5,135,000. Institutional investors and hedge funds own 91.71% of the company’s stock.

Spruce Biosciences Stock Performance

NASDAQ SPRB opened at $47.10 on Wednesday. The stock has a market cap of $129.62 million, a PE ratio of -1.29 and a beta of 3.12. The company has a current ratio of 4.67, a quick ratio of 4.67 and a debt-to-equity ratio of 0.16. Spruce Biosciences has a twelve month low of $4.77 and a twelve month high of $240.00. The stock has a fifty day simple moving average of $55.66 and a 200-day simple moving average of $67.39.

Spruce Biosciences (NASDAQ:SPRB – Get Free Report) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($8.94) earnings per share for the quarter, missing analysts’ consensus estimates of ($7.93) by ($1.01). Equities analysts anticipate that Spruce Biosciences will post -22.24 earnings per share for the current year.

About Spruce Biosciences

(Get Free Report)

Spruce Biosciences, Inc is a clinical-stage biopharmaceutical company dedicated to developing therapies for rare endocrine and dermatological disorders. Headquartered in San Diego, California, Spruce focuses on conditions with significant unmet medical needs, employing a precision medicine approach to identify and advance treatment candidates through late-stage clinical trials.

The company’s lead asset, tildacerfont, is an oral corticotropin-releasing factor type 1 (CRF1) receptor antagonist being evaluated for the treatment of congenital adrenal hyperplasia (CAH), a genetic disorder characterized by insufficient cortisol production and excess androgen levels.

Featured Stories

Analyst Recommendations for Spruce Biosciences (NASDAQ:SPRB)

Receive News & Ratings for Spruce Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spruce Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.